Indo-Bangla Pharmaceuticals Limited

DSE:IBP Stock Report

Market Cap: ৳976.1m

Indo-Bangla Pharmaceuticals Valuation

Is IBP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IBP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IBP (BDT8.7) is trading below our estimate of fair value (BDT9.05)

Significantly Below Fair Value: IBP is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IBP?

Key metric: As IBP is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IBP. This is calculated by dividing IBP's market cap by their current revenue.
What is IBP's PS Ratio?
PS Ratio4.6x
Sales৳211.61m
Market Cap৳976.12m

Price to Sales Ratio vs Peers

How does IBP's PS Ratio compare to its peers?

The above table shows the PS ratio for IBP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.5x
CENTRALPHL Central Pharmaceuticals
9.1xn/a৳1.0b
SILVAPHL Silva Pharmaceuticals
2.2xn/a৳1.3b
SILCOPHL Silco Pharmaceuticals
3.9xn/a৳1.7b
ADVENT Advent Pharma
2.8xn/a৳1.5b
IBP Indo-Bangla Pharmaceuticals
4.8xn/a৳1.0b

Price-To-Sales vs Peers: IBP is expensive based on its Price-To-Sales Ratio (4.8x) compared to the peer average (4.6x).

Price to Sales Ratio vs Industry

How does IBP's PS Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

48 CompaniesPrice / SalesEstimated GrowthMarket Cap
IBP 4.6xIndustry Avg. 2.6xNo. of Companies87PS0246810+
48 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IBP is expensive based on its Price-To-Sales Ratio (4.8x) compared to the Asian Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is IBP's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IBP PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IBP's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies